Skip to content
Krypton AI
Client portal
Demo

Book 30 minutes with us.

We prepare a first read on your company: your story, the funds that own your peers, and a short briefing. A person reviews it before we meet.

Prefer email? contact@kryptonai.io

M-tron Industries, Inc.

Ticker
MPTI
Sector
Electronic components
Dated
22 September 2026
Stance
BUY (initiated)

Priced as a defense parts maker that ran too far and diluted holders. Backlog of $84.0m covers most of next year, and $96.2m of cash with no debt funds acquisitions.

Price (29 Sep 26)
$76.73
Price target (12m)
$89.70
Scenario value*
$87.12
Bear / Base / Bull
$61.93 / $89.70 / $107.16
Market cap
$333.4M
Enterprise value
$237.3M
Free float
94.0% of S/O
Avg daily vol, 3m
185k / $15.5M
Short interest
8.3% float, +1.3pt
Institutional own.
67.2%
Largest holder
T. Rowe Price, 5.9%
Insider and board
5.7%

*Probability-weighted, 25/50/25, over 12 to 24 months. Price target is the base case, rounded to the nearest ten cents.

The thesis

  1. The margin dip is non-cash pay and tariffs, not pricing. Adding back about $0.5m of bonus stock compensation puts Q2 gross margin near 44.5%, in line with 44.4% for all of 2025.
  2. The backlog already covers most of next year. Backlog was $84.0m at June, up 37.2% and about 1.4x trailing revenue, and net income rose 19.9% while diluted EPS fell on the share count.
  3. The balance sheet turned Mtron into a buyer. It holds $96.2m of cash, no borrowings and an undrawn revolver, and management said it still hopes to close a deal this year.
  4. The next leg of growth is already being contracted for 2028. Defense primes signed seven-year missile agreements, and products launched a year ago have brought in $12m of orders.

Read the whole thing

The business, the market, the financials, the valuation with its scenarios, the risks and the catalysts. A PDF of 6 pages, 704 KB, sent to you, free.

M-tron Industries, Inc.

The full report, free. We send it as a PDF attachment, and we use the address for new research and nothing else.

Independent research. This is not investment advice and is not a recommendation to buy or sell any security. Please consult an accredited financial adviser before making any decision.

Comments

No comments yet.

Comments are read before they appear.